Allogeneic stem cell transplantation is increasingly considered as a curative though risky treatment option for adults with sickle cell disease. Little is known about attitudes of adult patients and their health care providers regarding the risks and benefits of transplantation. A survey of 100 patients and their health care providers was undertaken. Assessment of risk was by a reference gamble paradigm. Comparison was made of the characteristics of those accepting substantial risk vs those not accepting risk, as well as assessment of agreement on risks recommended by health care providers and accepted by patients. Sixty-three of 100 patients were willing to accept some short-term risk of mortality in exchange for the certainty of cure. Fifteen patients were willing to accept more than 35% mortality risk. No differences in patient or disease-related variables were identified between those accepting risk and those not accepting risk. There was no agreement between the recommendations of health care providers and the risk accepted by patients. A substantial proportion of adults with sickle cell disease are interested in curative treatment, at the expense of considerable risk. The decision to accept risk is influenced by individual patient values that cannot be easily quantified and that do not correlate with the assessment of the health care provider. Given the substantial interest in curative therapy, education about and consultation for allogeneic stem cell transplantation in sickle cell patients should be encouraged. Bone Marrow Transplantation (2001) 28, 545-549. Keywords: sickle cell disease; stem cell transplantation; risk; survey Sickle cell disease is a common congenital disorder with major implications for the health and longevity of affected 1 Several mature studies of allogeneic transplantation in children with sickle cell disease indicate a cure rate of 80%, a transplant-related mortality of less than 10% and a risk for serious complications (ie graft failure, grade III-IV acute GVHD and extensive chronic GVHD) of less than 10%.
individuals.
1 Several mature studies of allogeneic transplantation in children with sickle cell disease indicate a cure rate of 80%, a transplant-related mortality of less than 10% and a risk for serious complications (ie graft failure, grade III-IV acute GVHD and extensive chronic GVHD) of less than 10%. 2, 3 In one study, survival and cure rates were even better in children with early stage sickle cell disease. 2 In adults, sickle cell disease causes considerably more morbidity and mortality than in children, and no satisfactory medical treatment exists. 1 Allogeneic transplantation has until recently not been considered for adults with severe sickle cell disease, because of their perceived inability to tolerate intensive conditioning regimens. In order to address this dilemma, new conditioning regimens with much reduced toxicity, have been proposed. 4, 5 Such treatments are investigational and morbidity and mortality must be anticipated. How much risk is acceptable to adults with sickle cell disease is unknown.
The attitude of adults with sickle cell disease toward the illness and its treatment is influenced by a combination of social, psychological, intellectual and medical factors. Some patients may be willing to take considerable risks to be 'liberated' from the illness, others may be 'used' to the disease and the limitations on life style and life expectancy it imposes. In recommending treatments, physicians are influenced by equally complex but different motivations than are the patients. Concerns over risk, and concern over patient compliance may cause reluctance to recommend high-risk procedures. Severity of symptoms, debilitating complications and risk of death, may justify the recommendation of high-risk interventions. The very different viewpoint of patients and health care professionals can lead to different attitudes toward the risks of transplantation. [6] [7] [8] In a survey conducted almost 10 years ago, Kodish et al, 9 interviewed 67 parents regarding the risks they were willing to accept in order for their child with sickle cell disease to undergo potentially curative treatment. We conducted a similar survey of adults with sickle cell disease, the majority of whom had been followed for a prolonged period of time at one center. The purpose of this survey was to determine what would constitute an acceptable death rate of a curative treatment for adults with sickle cell disease. We also conducted an interview of the staff members and physicians involved in the long-term care of these patients, to establish the rate of agreement between risks accepted by patients and the recommendations of the care-givers.
Materials and methods
After obtaining informed consent, we interviewed 100 adults with sickle cell disease. The large majority (n = 93) of subjects were patients attending the UIC sickle cell clinic. All consecutive patients attending the clinic during a period of 3 weeks, were asked to participate, and those who agreed, took the survey while waiting for their doctor's visit. An additional small group (n = 7) of subjects were selected from patients belonging to a sickle cell support group in the Chicago suburbs and were interviewed by telephone. We conducted a structured interview with each patient. After obtaining relevant information about the demographic characteristics of the family and the patient's medical history, we described the process of bone marrow transplantation. The information we gave patients about bone marrow transplantation was based on the survey instrument used by Kodish et al. 9 A physician who was knowledgeable about both bone marrow transplantation and sickle cell disease, conducted the interviews. The patients were given several opportunities to ask questions. The interview did not proceed until the interviewer was certain that patients understood the information they had been given. We assessed patient's decisions about acceptable risks of mortality and morbidity by using questions based on the standard reference-gamble paradigm. 10 This is the same technique as was used in the prior pediatric study. Patients were asked whether they would consent to bone marrow transplantation in various hypothetical situations. In the first situation, bone marrow transplantation was described as offering 100% survival (no risk of mortality from the transplantation) and certain cure of sickle cell disease. In subsequent descriptions, the mortality rate associated with bone marrow transplantation was gradually increased by 5% increments. In this way, each patient indicated the highest risk of mortality that he or she would accept in exchange for the prospect of cure. The first situation in which the patient answered 'No' was registered as the point of too much risk, and this section of the interview was concluded. For example, the fourth question read as follows: 'Suppose that for the transplant 85% lived and 15% died from the treatment. That is: 85 out of every 100 patients lived and were cured of sickle cell disease, but 15 out of 100 died in the first 30 days after the treatment. If these were the risks would you want to have this treatment?' To analyze our data, we compared patients who accepted some risk associated with transplantation (at least 10%) with those who did not, by using the Fisher exacttest for dichotomous variables and the Wilcoxon rank-sum test for ordinal variables. 11 The 10% level of risk is similar to the treatment-related death rate that has been observed in pediatric studies of transplantation for sickle cell disease. 2, 3 The same level was also used as a cut-off in the prior pediatric study. We tested for differences in the following variables between the two groups: age, gender, level of education, number of transfusions, WBC count, creatinine level, level of HB F, prior stroke, history of surgery, taking pain medication, taking hydroxyurea. Some of the variables studied were similar to the ones used in the prior pediatric study. Others, such as WBC, creatinine level, use of hydroxyurea have been related to survival or frequency of painful crises. 1, 12 WBC, creatinine level and percentage hemoglobin F were obtained by chart review. The data for all other variables were obtained by self-reporting from the subject.
In a second part of the study, six health care providers were interviewed. They were familiar with the patients, but did not have access to the medical record at the time of the interview. They were asked whether they would recommend transplantation for each of their patients in the various hypothetical situations that had been described to the patients before.
To analyze this data set, we again compared patients who accepted some risk for transplantation (at least 10%) with those who did not. Then we matched the recommendations of the health care practitioners with the patients' decision. The rate of agreement between the the health care providers and the patients was calculated using a kappa statistic (chance corrected proportional agreement). 13 A value of kappa less than 0.2 indicates poor agreement; values between 0.2 and 0.4 indicate a fair level of agreement.
The study was approved by the institutional review board of the University of Illinois at Chicago.
Results
We approached 103 patients with sickle cell disease between 26 February 1999 and 18 March 1999. Three patients we approached, declined to participate. Therefore 100 patients were interviewed. The patients ranged from age 19 to age 60, with a median age of 36 years. All the patients had homozygous disease. Other patient characteristics are summarized in Table 1 .
Twenty-eight patients were unwilling to accept any risk of short-term mortality (death within 30 days) in order to be cured of sickle cell disease. These patients said 'No' to transplantation at the 100% survival-cure level: 100% probability of cure and 0% short-term mortality. Another nine patients were not willing to accept any significant risk (Figure 1 ). These nine said 'Yes' to transplantation at the 100% survival-cure level, but said no at the 95% level (95% probability of cure and 5% risk of short-term mortality). Sixty-three of the 100 patients were willing to accept a risk greater than 5% short-term mortality in exchange for a cure. Forty-six were willing to accept a risk of greater than 15%, and 20 patients were willing to accept a risk greater than 30%. Twelve patients were willing to accept a risk of shortterm mortality higher than 40%.
In contrast to the pediatric study, we could not determine any association between patient or disease characteristics and the risk accepted. There were no differences in patient, disease or treatment-related parameters between those willing to accept at least a 10% risk, compared with those not willing to accept such a risk (Table 1) .
In the second part of the study, we interviewed six health 547 Figure 1 Number of patients with sickle cell disease who said they would choose bone marrow transplantation at different estimates of the mortality rate associated with the procedure. There were 100 patients in the study. Twenty-eight said they would not consent to the procedure, even if there were no risks associated with it. The numbers over the bars indicate how many patients said they would consent to the procedure.
care providers, two doctors and four nurses, who provided the continuum of care in the sickle cell clinic and were therefore familiar with the patients. The health care providers were asked what risk of transplant they would consider acceptable for each of the patients. The comparison between recommendations of the health care providers and patient's decisions are tabulated in Table 2 . The proportion of patients for whom transplant would be recommended 
Discussion
Ten years ago, Kodish et al, 9 showed that there is considerable interest in allogeneic transplantation among parents of children with sickle cell disease. Nevertheless, accrual to studies of allogeneic transplantation has been slow in the United States. 3 Numerous factors play a role in the decision to offer transplantation to a patient. The most important one is that only a small percentage of patients have HLAidentical siblings.
14 Another factor is the wide disparity in the concept of who is, or is not qualified for transplant. In a survey of 22 centers, the proportion of patients that qualified for transplant protocols ranged from 0.9% to 36% in different centers, indicating radically different attitudes among physicians regarding indications for transplantation in children. Some would recommend transplantation to all children with hemoglobinopathies, 2,15 others recommend conservative treatment in the large majority. 16, 17 Sickle cell disease constitutes an even greater problem in adults, but transplantation is only starting to be explored, and little is known about patients' and doctors' attitudes toward the risks of transplantation. In our survey, we attempted to quantify the acceptable risk by presenting adults with sickle cell disease with a set of hypothetical scenarios. Forty-six percent of the patients we interviewed would be willing to consent to stem cell transplantation with a 15% or greater risk of short-term mortality. These data are strikingly similar to those obtained by Kodish et al, 9 in their survey of parents of children with sickle cell disease. Kodish et al found that the risk considered acceptable by parents was related to the level of education, and the number of children with sickle cell disease in the family. In adults, we did not identify patient-or disease-related variables that could predict the risk a patient would be willing to take for bone marrow transplantation. In addition to interviewing the patients, we surveyed their health care providers. Among health care providers, perceptions about acceptability of risk varied considerably. There was no agreement between the recommendations of the health care providers and the risks acceptable to the patients themselves.
The data of this survey should be interpreted with caution. By necessity, the hypothetical scenarios presented to the subjects provide limited information about the procedure and implications of transplant. Information on conditioning therapy, acute and chronic GVHD and late sideeffects on fertility was not provided and might have further influenced the patient's thoughts. 18 The survey also does not provide us with any insights into the motivations behind patient's decisions or recommendations of the health care providers.
Despite these limitations, two credible conclusions emerge. First, there is a considerable interest among adults with sickle cell disease in a potentially curative treatment, despite a risk of treatment-related death. Second, there is a lack of agreement between physicians' recommendations and patients' attitudes. The conclusion from the earlier report by Kodish et al continues to be applicable: 'Patients may not think about risks and benefits the way doctors do'. 9 If such is the case, should physicians discuss transplantation with their patients, even though they may not feel Table 2 Rates of agreement between risks acceptable to patients and risk that their health-care providers consider acceptable There were some subjects with whom individual health care providers were not familiar, and for whom they declined to provide a recommendation.
that it is an appropriate procedure for a specific patient? In our opinion, the answer is Yes. Providing appropriate information and education about all treatment alternatives in a way that promotes patient autonomy and rational decision-making, is one of the fundamental duties of the physician. 19, 20 The core of patients rights is the right to receive care from an accountable physician who shares all relevant information with the patient, and who guarantees the patient the right to make the final decision about treatment. 21 The right to information includes the right to be informed about reasonable alternative treatments, including research protocols that are relevant to the patient's condition. 21 Although the treatment choice of the patient may not be in accordance with the physician's recommendations, competent autonomous decisions should be honored. 19 In other words, the patient's autonomy and dignity should be respected, and medical paternalism is to be avoided. 22 Given the interest of a substantial proportion of patients in curative approaches, and despite their risks, it is imperative that adults with sickle cell disease be provided information about and access to allogeneic transplant trials. Careful attention to informed consent, including a thorough discussion of the risks, benefits and alternatives to marrow transplantation for sickle cell disease, will empower patients to make their own decisions about this promising but risky therapy.
